BLACKSBURG, VA. August 15, 2017—The oral, small-molecule therapeutic known as BT-11 is on the fast track to becoming the new drug for treating inflammatory bowel disease (IBD), a widespread and debilitating disease afflicting over 4 million people worldwide. From discovery to investigational new drug (IND) submission in less than 12 months, the latest findings on BT-11 will be published in this month’s issue of the Journal of Medicinal Chemistry.
Landos Biopharma’s seminal publication can be found: http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00412
There is an unmet clinical need for safer, more effective medications for IBD variants such as Crohn’s disease and ulcerative colitis. This publication outlines the steps for lead selection, optimization, and validation in animal models of IBD. The findings also provide novel evidence that oral treatment with BT-11 reduces gut inflammation and inflammatory lesions in single-digit doses by 90% in mice with IBD.
BT-11 is based on a novel mechanism of action targeting the Lanthionine Synthetase C-like 2 (LANCL2) pathway in immune cells of the gut. LANCL2 activation by BT-11 intercepts IBD at two levels: by decreasing the production of inflammatory mediators and increasing anti-inflammatory molecules in the gut. The study demonstrates the selectivity of BT-11 for LANCL2; the protective effects of BT-11 in IBD were abrogated following the genetic ablation of the LANCL2 target in animal models.
“This is a seminal paper in a series of upcoming publications that validates BT-11 as a first-in-class oral therapeutic for IBD,” said Dr. Raquel Hontecillas, LANDOS Chief Scientific Officer. “We are very excited to see chief results of the BT-11 program published in such a reputable, peer-reviewed journal. The development of BT-11 as on oral medication for IBD is an excellent example of how computational modeling accelerates the path to cures in IBD.”
The Journal of Medicinal Chemistry is the top medicinal chemistry journal worldwide, publishing novel studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.
“This recent paper further substantiates LANCL2 technology as a therapeutic target for IBD and reports our initial, nonclinical findings on BT-11, a small-molecule therapeutic that outperforms current drugs and INDs in mouse models of IBD,” said Dr. Josep Bassaganya-Riera, LANDOS President and CEO. “Our safety studies in rats demonstrate a benign safety profile for BT-11 at doses that are 100 times higher than its effective dose. We anticipate completing the remaining IND-enabling studies in order to file an application for BT-11 by 2018. In addition, we are currently raising $10 million in Series-A financing to advance BT-11 to first in human studies.”
About Landos Biopharma, Inc.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract
for treatment of inflammatory bowel disease (IBD) and is in Phase 1 clinical testing for Crohn’s disease and ulcerative colitis. Landos also has a robust pipeline of compounds for other autoimmune diseases. For more information, please visit www.landosbiopharma.com or contact firstname.lastname@example.org or follow us @Landosbio.
For Media Requests: